125 related articles for article (PubMed ID: 32915419)
1. Phase 1 study of 2 high dose intensity schedules of the pan-Notch inhibitor crenigacestat (LY3039478) in combination with prednisone in patients with advanced or metastatic cancer.
Azaro A; Baldini C; Rodon J; Soria JC; Yuen E; Lithio A; Oakley G; Benhadji KA; Massard C
Invest New Drugs; 2021 Feb; 39(1):193-201. PubMed ID: 32915419
[TBL] [Abstract][Full Text] [Related]
2. First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer.
Massard C; Azaro A; Soria JC; Lassen U; Le Tourneau C; Sarker D; Smith C; Ohnmacht U; Oakley G; Patel BKR; Yuen ESM; Benhadji KA; Rodon J
Ann Oncol; 2018 Sep; 29(9):1911-1917. PubMed ID: 30060061
[TBL] [Abstract][Full Text] [Related]
3. A phase 1 study of crenigacestat (LY3039478), the Notch inhibitor, in Japanese patients with advanced solid tumors.
Doi T; Tajimi M; Mori J; Asou H; Inoue K; Benhadji KA; Naito Y
Invest New Drugs; 2021 Apr; 39(2):469-476. PubMed ID: 32939607
[TBL] [Abstract][Full Text] [Related]
4. A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumors.
Azaro A; Massard C; Tap WD; Cassier PA; Merchan J; Italiano A; Anderson B; Yuen E; Yu D; Oakley G; Benhadji KA; Pant S
Invest New Drugs; 2021 Aug; 39(4):1089-1098. PubMed ID: 33686452
[TBL] [Abstract][Full Text] [Related]
5. A phase 1b study of crenigacestat (LY3039478) in combination with gemcitabine and cisplatin or gemcitabine and carboplatin in patients with advanced or metastatic solid tumors.
Massard C; Cassier PA; Azaro A; Anderson B; Yuen E; Yu D; Oakley G; Benhadji KA; Pant S
Cancer Chemother Pharmacol; 2022 Oct; 90(4):335-344. PubMed ID: 36030462
[TBL] [Abstract][Full Text] [Related]
6. Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma.
Even C; Lassen U; Merchan J; Le Tourneau C; Soria JC; Ferte C; Ricci F; Diener JT; Yuen E; Smith C; Oakley GJ; Benhadji KA; Massard C
Invest New Drugs; 2020 Apr; 38(2):402-409. PubMed ID: 30953269
[TBL] [Abstract][Full Text] [Related]
7. Phase 1 study to evaluate Crenigacestat (LY3039478) in combination with dexamethasone in patients with T-cell acute lymphoblastic leukemia and lymphoma.
Borthakur G; Martinelli G; Raffoux E; Chevallier P; Chromik J; Lithio A; Smith CL; Yuen E; Oakley GJ; Benhadji KA; DeAngelo DJ
Cancer; 2021 Feb; 127(3):372-380. PubMed ID: 33107983
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors.
Tolcher AW; Messersmith WA; Mikulski SM; Papadopoulos KP; Kwak EL; Gibbon DG; Patnaik A; Falchook GS; Dasari A; Shapiro GI; Boylan JF; Xu ZX; Wang K; Koehler A; Song J; Middleton SA; Deutsch J; Demario M; Kurzrock R; Wheler JJ
J Clin Oncol; 2012 Jul; 30(19):2348-53. PubMed ID: 22529266
[TBL] [Abstract][Full Text] [Related]
9. A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors.
Diaz-Padilla I; Hirte H; Oza AM; Clarke BA; Cohen B; Reedjik M; Zhang T; Kamel-Reid S; Ivy SP; Hotte SJ; Razak AA; Chen EX; Brana I; Wizemann M; Wang L; Siu LL; Bedard PL
Invest New Drugs; 2013 Oct; 31(5):1182-91. PubMed ID: 23860641
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the effects of an oral notch inhibitor, crenigacestat (LY3039478), on QT interval, and bioavailability studies conducted in healthy subjects.
Yuen E; Posada M; Smith C; Thorn K; Greenwood D; Burgess M; A Benhadji K; Ortega D; Chinchen L; Suico J
Cancer Chemother Pharmacol; 2019 Mar; 83(3):483-492. PubMed ID: 30539232
[TBL] [Abstract][Full Text] [Related]
11. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA
Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719
[TBL] [Abstract][Full Text] [Related]
12. Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors.
Dees EC; Infante JR; Cohen RB; O'Neil BH; Jones S; von Mehren M; Danaee H; Lee Y; Ecsedy J; Manfredi M; Galvin K; Stringer B; Liu H; Eton O; Fingert H; Burris H
Cancer Chemother Pharmacol; 2011 Apr; 67(4):945-54. PubMed ID: 20607239
[TBL] [Abstract][Full Text] [Related]
13. A phase I/II study of carfilzomib 2-10-min infusion in patients with advanced solid tumors.
Papadopoulos KP; Burris HA; Gordon M; Lee P; Sausville EA; Rosen PJ; Patnaik A; Cutler RE; Wang Z; Lee S; Jones SF; Infante JR
Cancer Chemother Pharmacol; 2013 Oct; 72(4):861-8. PubMed ID: 23975329
[TBL] [Abstract][Full Text] [Related]
14. Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors.
Infante JR; Camidge DR; Mileshkin LR; Chen EX; Hicks RJ; Rischin D; Fingert H; Pierce KJ; Xu H; Roberts WG; Shreeve SM; Burris HA; Siu LL
J Clin Oncol; 2012 May; 30(13):1527-33. PubMed ID: 22454420
[TBL] [Abstract][Full Text] [Related]
15. First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13).
Wicki A; Brown N; Xyrafas A; Bize V; Hawle H; Berardi S; Cmiljanović N; Cmiljanović V; Stumm M; Dimitrijević S; Herrmann R; Prêtre V; Ritschard R; Tzankov A; Hess V; Childs A; Hierro C; Rodon J; Hess D; Joerger M; von Moos R; Sessa C; Kristeleit R
Eur J Cancer; 2018 Jun; 96():6-16. PubMed ID: 29660598
[TBL] [Abstract][Full Text] [Related]
16. Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies.
Mahadevan D; Chiorean EG; Harris WB; Von Hoff DD; Stejskal-Barnett A; Qi W; Anthony SP; Younger AE; Rensvold DM; Cordova F; Shelton CF; Becker MD; Garlich JR; Durden DL; Ramanathan RK
Eur J Cancer; 2012 Dec; 48(18):3319-27. PubMed ID: 22921184
[TBL] [Abstract][Full Text] [Related]
17. Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory cancer.
Schöffski P; Thate B; Beutel G; Bolte O; Otto D; Hofmann M; Ganser A; Jenner A; Cheverton P; Wanders J; Oguma T; Atsumi R; Satomi M
Ann Oncol; 2004 Apr; 15(4):671-9. PubMed ID: 15033678
[TBL] [Abstract][Full Text] [Related]
18. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial.
Heery CR; O'Sullivan-Coyne G; Madan RA; Cordes L; Rajan A; Rauckhorst M; Lamping E; Oyelakin I; Marté JL; Lepone LM; Donahue RN; Grenga I; Cuillerot JM; Neuteboom B; Heydebreck AV; Chin K; Schlom J; Gulley JL
Lancet Oncol; 2017 May; 18(5):587-598. PubMed ID: 28373007
[TBL] [Abstract][Full Text] [Related]
19. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.
Bendell JC; Rodon J; Burris HA; de Jonge M; Verweij J; Birle D; Demanse D; De Buck SS; Ru QC; Peters M; Goldbrunner M; Baselga J
J Clin Oncol; 2012 Jan; 30(3):282-90. PubMed ID: 22162589
[TBL] [Abstract][Full Text] [Related]
20. A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancer.
Pant S; Jones SF; Kurkjian CD; Infante JR; Moore KN; Burris HA; McMeekin DS; Benhadji KA; Patel BKR; Frenzel MJ; Kursar JD; Zamek-Gliszczynski MJ; Yuen ESM; Chan EM; Bendell JC
Eur J Cancer; 2016 Mar; 56():1-9. PubMed ID: 26798966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
